Treatment with CernitinTM of induced urinary bladder inflammation downregulates relevant pro-inflammatory biomarkers – an experimental in vivo rodent model
DOI:
https://doi.org/10.2340/sju.v61.45606Keywords:
Cytokines, inflammatory biomarkers, chronic cystitis, interstitial cystitis;, bladder pain syndrome, animal modelAbstract
Objective: Chronic inflammation of the urinary bladder is associated with the bladder pain syndrome. The treatment alternatives in humans are far from satisfactory and need further attention. Well-established preclinical models have shown that pro-inflammatory cytokines contribute to the progress of the inflammatory response behind pain and hyperalgesia. Previously presented results indicate that treatment with CernitinTM pollen extracts active pharmaceutical ingredients (APIs) (Cernitin GBX and Cernitin T60) significantly alleviated pain in cyclophosphamide-induced urinary bladder inflammation in a rodent model through downregulation of PGD2 and cyclooxygenase-2 (COX-2) mediators when compared to the vehicle alone. The objective was to extend the original study by exploring the correlation between the two APIs and cytokines expression and to identify a possible biomarker pattern.
Material and method: The Olink® Target 48 Mouse Cytokine assay was conducted on the homogenised tissue extracts of the bladder wall with induced inflammation from a previous study to identify the potential impacts on protein biomarkers.
Results: The test revealed that treatment with the APIs significantly downregulated the cytokines interleukin (IL)-1α, IL-2, IL-4, IL-6, and with trend to significance the biomarkers IL-12 α, β, CCL4 and fibroblast growth factor 21 when administered in combination (GBX+T60) or each component alone, compared to vehicle controls.
Conclusion: This study identified seven cytokines that were significantly or markedly reduced. The results suggest that CernitinTM APIs impact a series of key pro-inflammatory biomarkers demonstrating an ability to restrain inflammation. Therefore, they warrant further investigation as potential therapeutic candidates
Downloads
References
Jhang JF, Kuo HC. Pathomechanism of interstitial cystitis/bladder pain syndrome and mapping the heterogeneity of disease. Int Neurourol J. 2016;20:95–104.
https://doi.org/10.5213/inj.1632712.356 DOI: https://doi.org/10.5213/inj.1632712.356
Neuhaus J, Berndt-Paetz M, Gonsior A. Biomarkers in the light of the etiopathology of IC/BPS. Diagnostics. 2021;11(12):2231.
https://doi.org/10.3390/diagnostics11122231 DOI: https://doi.org/10.3390/diagnostics11122231
Quentin Clemens J, Erickson DR, Varela NP, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2022;208(1):34–42.
https://doi.org/10.1097/JU.0000000000002756 DOI: https://doi.org/10.1097/JU.0000000000002756
Augé C, Gamé X, Vergnolle N, et al. Characterization and validation of a chronic model of cyclophosphamide-induced interstitial cystitis/bladder pain syndrome in rats. Front Pharmacol. 2020;11:1305.
https://doi.org/10.3389/fphar.2020.01305 DOI: https://doi.org/10.3389/fphar.2020.01305
Zheng Z, Zhang J, Zhang C, et al. The study on the function and cell source of interleukin-6 in interstitial cystitis/bladder painful syndrome rat model. Immun Inflamm Dis. 2021;9(4):1520–1528.
https://doi.org/10.1002/iid3.505 DOI: https://doi.org/10.1002/iid3.505
Augé C, Dizeyi N, Ramnemark L, et al. Experimental in vivo model to evaluate the impact of CernitinTM on pain response on induced chronic bladder inflammation. Scand J Urol. 2022;56(4):320–328.
https://doi.org/10.1080/21681805.2022.2090602 DOI: https://doi.org/10.1080/21681805.2022.2090602
Tay C, Grundy L. Animal models of interstitial cystitis/bladder pain syndrome. Front Physiol. 2023;14:1232017.
https://doi.org/10.3389/fphys.2023.1232017 DOI: https://doi.org/10.3389/fphys.2023.1232017
Wagenlehner FM, Schneider H, Ludwig M, et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol. 2009;56(3):544–551.
https://doi.org/10.1016/j.eururo.2009.05.046 DOI: https://doi.org/10.1016/j.eururo.2009.05.046
Chabot S, Dizeyi N, Ramnemark L, et al. Impact of CernitinTM on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms. Phytomedicine Plus. 2021;1:100057.
https://doi.org/10.1016/j.phyplu.2021.100057 DOI: https://doi.org/10.1016/j.phyplu.2021.100057
Turner MD, Nedjai B, Hurst T, et al. Cytokines and chemokines: at the crossroads of cell signaling and inflammatory disease. Biochim Biophys Acta. 2014;1843(11):2563–2582.
https://doi.org/10.1016/j.bbamcr.2014.05.014 DOI: https://doi.org/10.1016/j.bbamcr.2014.05.014
Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45(2):27–37.
https://doi.org/10.1097/AIA.0b013e318034194e DOI: https://doi.org/10.1097/AIA.0b013e318034194e
Yu WR, Jiang YH, Jhang JF, et al. Use of urinary cytokine and chemokine levels for identifying bladder conditions and predicting treatment outcomes in patients with interstitial cystitis/bladder pain syndrome. Biomedicines. 2022;10(5):1149.
https://doi.org/10.3390/biomedicines10051149 DOI: https://doi.org/10.3390/biomedicines10051149
Abbas AK. The surprising story of IL-2: from experimental models to clinical application. Am J Pathol. 2020;190(9):1776–1781.
https://doi.org/10.1016/j.ajpath.2020.05.007 DOI: https://doi.org/10.1016/j.ajpath.2020.05.007
Torres T, Mendes-Bastos P, Cruz MJ, et al. Interleukin-4 and atopic dermatitis: why does it matter? A narrative review. Dermatol Ther. 2025;15(3):579–597.
https://doi.org/10.1007/s13555-025-01352-y DOI: https://doi.org/10.1007/s13555-025-01352-y
Ullrich KA-M, Schulze LL, Paap E-M, et al. Immunology of IL-12: an update on functional activities and implications for disease. EXCLI J. 2020;19:1563–1589.
https://doi.org/10.17179/excli2020-3104
Chang TT, Yang HY, Chen C, et al. CCL4 inhibition in atherosclerosis: effects of plaque stability, endothelial cell adhesiveness, and macrophages activation. Int J Mol Sci. 2020;21(18):6567.
https://doi.org/10.3390/ijms21186567 DOI: https://doi.org/10.3390/ijms21186567
Yang M, Liu C, Jiang N, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol. 2023;14:121220426.
https://doi.org/10.3389/fendo.2023.1220426 DOI: https://doi.org/10.3389/fendo.2023.1220426
Kureshi CT, Dougan SK. Cytokines in cancer. Cancer Cell. 2025;43(1):15–35.
https://doi.org/10.1016/j.ccell.2024.11.011 DOI: https://doi.org/10.1016/j.ccell.2024.11.011
Wullt B, Butler DSC, Ambite I, et al. Immunomodulation – a molecular solution to treating patients with severe bladder pain syndrome? Eur Urol Open Sci. 2021:31:49–58.
https://doi.org/10.1016/j.euros.2021.07.003 DOI: https://doi.org/10.1016/j.euros.2021.07.003
Smaldone MC, Vodovotz Y, Tyagi Y, et al. Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology. 2009;73(2):421–426.
https://doi.org/10.1016/j.urology.2008.07.031 DOI: https://doi.org/10.1016/j.urology.2008.07.031
Jiang YH, Jhang JF, Hsu YH, et al. Usefulness of urinary biomarkers for assessing bladder condition and histopathology in patients with interstitial cystitis/bladder pain syndrome. Int J Mol Sci. 2022;23(19):12044.
https://doi.org/10.3390/ijms231912044 DOI: https://doi.org/10.3390/ijms231912044
Dinarello CA, Simon A, Van Der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11(8):633–652.
https://doi.org/10.1038/nrd3800 DOI: https://doi.org/10.1038/nrd3800
Dizeyi N, Mattisson IY, Ramnemark L, et al. The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia: an in vitro study. Phytother Res. 2019;33(9):2457–2464.
https://doi.org/10.1002/ptr.6438 DOI: https://doi.org/10.1002/ptr.6438
Sant GR, Kempuraj D, Marchand JE, et al. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology. 2007;69(4 Suppl):34–40.
https://doi.org/10.1016/j.urology.2006.08.1109 DOI: https://doi.org/10.1016/j.urology.2006.08.1109
Sugaya K, Nishijima S, Yamada T, et al. Molecular analysis of adrenergic receptor genes and interleukin-4/interleukin-4 receptor genes in patients with interstitial cystitis. J Urol. 2002;168(6):2668–2671.
https://doi.org/10.1016/S0022-5347(05)64241-3 DOI: https://doi.org/10.1016/S0022-5347(05)64241-3
Tait Wojno ED, Hunter CA, Stumhofer JS. The immunobiology of the interleukin-12 family: room for discovery. Immunity. 2019;50(4):851–870.
https://doi.org/10.1016/j.immuni.2019.03.011 DOI: https://doi.org/10.1016/j.immuni.2019.03.011
Lemmon B, Kyrgiou M, Mullins E, et al. Cytokines in bladder pain syndrome: a review of the literature. Int Urogynecol J. 2024;35(6):1119–1129.
https://doi.org/10.1007/s00192-024-05778-4 DOI: https://doi.org/10.1007/s00192-024-05778-4
Zmigrodzka M, Rzepecka A, Krzyzowska M, et al. The cyclooxygenase-2/prostaglandin E 2 pathway and its role in the pathogenesis of human and dog hematological malignancies. J Physiol Pharmacol. 2018;69(5):653–661.
https://doi.org/10.26402/jpp.2018.5.01
Wang C, Li GW, Huang LY. Prostaglandin E2 potentiation of P2X3 receptor mediated currents in dorsal root ganglion neurons. Mol Pain. 2007;32:22.
https://doi.org/10.1186/1744-8069-3-22 DOI: https://doi.org/10.1186/1744-8069-3-22
De Brito TV, Dias Junior GJ, da Cruz Junior JS, et al. Gabapentin attenuates intestinal inflammation: role of PPAR-gamma receptor. Eur J Pharmacol. 2020;873:172974.
https://doi.org/10.1016/j.ejphar.2020.172974 DOI: https://doi.org/10.1016/j.ejphar.2020.172974
Augé C, Chene G, Dubourdeau M, et al. Relevance of the cyclophosphamide-induced cystitis model for pharmacological studies targeting inflammation and pain of the bladder. Eur J Pharmacol. 2013;707:32–40. DOI: https://doi.org/10.1016/j.ejphar.2013.03.008
https://doi.org/10.1016/j.ejphar2013.03.008
Akdere H, Blir B, Kuvan HC, et al. Interleukins in urological diseases. Discov Med. 2025;37:647–658.
https://doi.org/10.24976/Discov.Med.202537195.56 DOI: https://doi.org/10.24976/Discov.Med.202537195.56
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Nishtman Dizeyi, Celine Augé, Philippe Lluel, Magnus Grabe
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
